Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FTC OKs Pfizer-Wyeth merger

This article was originally published in The Tan Sheet

Executive Summary

The Federal Trade Commission clears Pfizer's $68 billion acquisition of Wyeth on the condition Pfizer sell half of Wyeth's animal health business to Boehringer Ingelheim Vetmedica. Pfizer announced in September that it would relinquish those assets. FTC noted while the companies' human drug portfolios are highly complementary, they do not raise anticompetitive concerns and consumers will not suffer because of the overlap. The firms also recently passed multiple other merger milestones, including obtaining approvals from the European Commission and stockholders (1"The Tan Sheet" July 27, 2009)

You may also be interested in...

Sales & Earnings In Brief

Schering-Plough consumer sales cool: Schering-Plough's consumer health sales fell 5 percent to $381 million in the firm's fiscal 2009 second quarter "primarily due to lower sales of sun care products due to the unseasonable weather," according to Chief Financial Officer Bob Bertollini. Sun care sales fell 17 percent to $96 million compared to $115 million during the year-ago quarter. Sales of laxative MiraLAX reached $36 million, a 30 percent increase, according to a July 21 earnings statement. The MiraLAX growth helped offset a 10 percent drop of OTCClaritin sales to $108 million in the April-June period, Bertollini said during a same-day earnings call. Schering expects its merger with Merck to close in the fourth quarter (1"The Tan Sheet" March 16, 2009)

Did Sarepta Need To Tell Investors About Its Vyondys 53 Dispute Resolution Request?

Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.

Sarepta’s Vyondys: Renal Toxicity Concerns That Delayed Approval Get Enhanced Postmarketing Scrutiny, Label Warning

Sarepta must perform enhanced pharmacovigilance for serious renal toxicity events and rhabdomyolysis with the Duchenne muscular dystrophy drug, which carries a label warning for renal toxicity. Approval letter includes 2024 target completion date for ESSENCE confirmatory trial.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts